Payment overview · 2025
General Payments
$1,132.21
59 reported records · 21 companies
Healthcare provider profile · identity verified
Trevor Whiting, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · MESA, AZ · NPI 1457755613
Verified facts
What the public records show
CMS Open Payments records show Trevor Whiting, PA-C received $1,132.21 in general payments during 2025 across 59 reported records.
Lilly USA, LLC accounted for 15.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $178.71 | 15.8% | 10 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $121.89 | 10.8% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $115.97 | 10.2% | 6 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $88.76 | 7.8% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $82.81 | 7.3% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $74.27 | 6.6% | 3 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $69.52 | 6.1% | 3 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $64.18 | 5.7% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $50.37 | 4.5% | 3 | 2025 |
| QOL Medical, LLC | Unresolved — no canonical attribution shown | $47.99 | 4.2% | 2 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $30.89 | 2.7% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.80 | 2.6% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.88 | 2.2% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $23.59 | 2.1% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $23.07 | 2.0% | 1 | 2025 |
| Biocon Biologics Inc | Unresolved — no canonical attribution shown | $21.66 | 1.9% | 1 | 2025 |
| Celltrion USA Inc. | Unresolved — no canonical attribution shown | $21.53 | 1.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.32 | 1.8% | 1 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $18.29 | 1.6% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $17.19 | 1.5% | 1 | 2025 |
| 3B Medical, Inc. | Unresolved — no canonical attribution shown | $6.52 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,132.21 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $158.28 | 6 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $121.89 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $115.97 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $90.75 | 5 | 2025 |
Source payment records
|
|||||
| OMVOH Normalized: omvoh |
Drug | Lilly USA, LLC | $87.96 | 5 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $82.81 | 5 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $64.18 | 3 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $64.18 | 3 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $64.18 | 3 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $64.18 | 3 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $50.37 | 3 | 2025 |
Source payment records
|
|||||
| Sucraid Normalized: sucraid |
Drug | QOL Medical, LLC | $47.99 | 2 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $30.89 | 3 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $26.28 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| Yesintek Normalized: yesintek |
Biological | Biocon Biologics Inc | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| VEGZELMA Normalized: vegzelma |
Biological | Celltrion USA Inc. | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| LUNA Normalized: luna |
Device | 3B Medical, Inc. | $6.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 76 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 385 | 115 |
| Losartan Potassium | Losartan Potassium | 313 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 273 | 87 |
| Atorvastatin Calcium | Atorvastatin Calcium | 272 | 83 |
| Metformin Hcl | Metformin Hcl | 203 | 64 |
| Lisinopril | Lisinopril | 186 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 159 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 158 | 58 |
| Trazodone Hcl | Trazodone Hcl | 143 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 41 |
| Gabapentin | Gabapentin | 138 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 131 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 122 | 42 |
| Simvastatin | Simvastatin | 120 | 33 |
| Omeprazole | Omeprazole | 116 | 39 |
| Glipizide | Glipizide | 101 | 34 |
| Potassium Chloride | Potassium Chloride | 92 | 30 |
| Sertraline Hcl | Sertraline Hcl | 84 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 30 |
| Methylprednisolone | Methylprednisolone | 81 | 76 |
| Furosemide | Furosemide | 78 | 32 |
| Meloxicam | Meloxicam | 78 | 42 |
| Alendronate Sodium | Alendronate Sodium | 77 | 22 |
| Ozempic | Semaglutide | 76 | 22 |
| Allopurinol | Allopurinol | 75 | 22 |
| Montelukast Sodium | Montelukast Sodium | 68 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 18 |
| Famotidine | Famotidine | 55 | 20 |
| Azithromycin | Azithromycin | 53 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 33 |
| Lovastatin | Lovastatin | 50 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 19 |
| Jardiance | Empagliflozin | 47 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 46 | 15 |
| Bupropion Xl | Bupropion Hcl | 44 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 15 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Ezetimibe | Ezetimibe | 39 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | suppressed |
| Carvedilol | Carvedilol | 35 | 11 |
| Levofloxacin | Levofloxacin | 35 | 31 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 29 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 29 |
| Metformin Hcl Er | Metformin Hcl | 32 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 26 |
| Prednisone | Prednisone | 32 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | 12 |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Eliquis | Apixaban | 29 | 11 |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 23 |
| Fenofibrate | Fenofibrate,micronized | 27 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | 18 |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 12 |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,132.21 · 59 records | Lilly USA, LLC | CHARTIS CATHETER, DUPIXENT, Hillrom - Vest System Model 105 Home Care, IBSRELA, JASCAYD, KEVEYIS, LUNA, OMVOH, OPSUMIT, Ohtuvayre, Ozempic, PULMONX CHARTIS TABLET CONSOLE, Rybelsus, SMARTVEST, Sucraid, TRELEGY ELLIPTA, TREMFYA, Tyvaso, VEGZELMA, WINREVAIR, YUPELRI, Yesintek, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE, ZERBAXA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error